YOLFTbeta
Maccura Biotechnology Co Ltd

Maccura Biotechnology Co Ltd

300463 · SHE · Healthcare / Diagnostics & Research

8.68CNY-0.22 (-2.47%)

Price History

Full chart

Market Stats

Previous Close8.90
Open8.89
Day Range8.63 – 8.89
52-Week Range7.87 – 14.20
Volume6.12M
Market Cap5.76B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.06
Dividend Yield0.00%
Beta0.20
50-Day Avg9.22
200-Day Avg10.27

About

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such as digital PCR and extraction systems, and PCR kits; urinalysis analyzer systems and semi-automatic urine analyzers; and hemostasis solutions, including coagulation and semi-automatic coagulation analyzers. It also provides clinical chemistry products, such as glycohemoglobin and protein analyzer, biochemistry systems, and chemistry regents; blood group product solutions; and pathology solutions, such as a liquid-based cytology processing system technologies. In addition, the company offers Mike Smart Lab, a patient-centered medical laboratory system solution based on automation and digital intelligence. Maccura Biotechnology Co.Ltd was founded in 1994 and is headquartered in Chengdu, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Wu Mingjian
  • Employees2.88K
  • HeadquartersNo.1006, Qihuang Road, Chengdu, China, 610219, China
  • Websitehttps://www.maccura.com

Leadership

  • Mr. Wu MingjianGM & Director · b. 1977
  • Ms. Shan YinChief Financial Officer · b. 1981
  • Mr. Ping YouAccounting Supervisor & Director · b. 1983
  • Mr. Xin LinSenior Director of the Human Resources Department · b. 1991
  • Mr. Deng Ming WangDirector and Chief Business Officer · b. 1966
  • Ms. Wei ShiSecretary & Chief Strategic Investment Officer · b. 1975
  • Ms. Ping YuSenior Director · b. 1981
  • Mr. Zhen WangProduction Director · b. 1971
  • Mr. Tengxiang LongDirector of R&D - Reagents · b. 1982
  • Mr. Weijia WangDirector of R&D - Instrumentation · b. 1984

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue521.31M606.15M779.43M934.85M1.07B1.49B1.97B2.69B3.22B3.70B3.98B3.61B2.90B2.55B2.17B
Growth (%)-+16.28%+28.59%+19.94%+13.94%+39.77%+32.32%+36.31%+20.02%+14.92%+7.47%-9.35%-19.75%-11.98%-14.84%
Cost of Revenue247.03M266.65M342.63M381.48M460.84M686.32M920.58M1.31B1.59B1.80B1.74B1.71B1.38B1.17B890.54M
Gross Profit274.28M339.51M436.79M553.36M604.33M802.46M1.05B1.37B1.63B1.91B2.24B1.90B1.51B1.38B1.28B
Gross Margin52.61%56.01%56.04%59.19%56.74%53.90%53.27%51.13%50.64%51.50%56.28%52.57%52.20%53.99%58.97%
Operating Expense121.54M131.44M184.92M260.36M302.01M400.38M541.41M774.84M936.31M917.99M1.03B1.08B1.18B1.21B1.23B
Operating Income152.74M208.07M251.88M293.00M302.32M402.08M508.00M598.25M695.84M989.69M1.21B817.39M331.14M169.97M54.76M
Operating Margin29.30%34.33%32.32%31.34%28.38%27.01%25.79%22.28%21.59%26.72%30.50%22.65%11.44%6.67%2.52%
EBITDA157.77M218.79M272.33M339.67M352.52M449.22M604.30M756.32M915.32M1.23B1.46B1.07B626.55M582.02M290.79M
EBITDA Margin30.26%36.09%34.94%36.33%33.09%30.17%30.68%28.16%28.40%33.26%36.75%29.60%21.64%22.84%13.40%
Net Income120.42M158.21M193.16M226.21M251.04M312.02M374.13M444.93M525.26M793.92M956.60M708.18M312.62M126.81M-35.83M
Net Income Margin23.10%26.10%24.78%24.20%23.57%20.96%18.99%16.57%16.30%21.43%24.03%19.63%10.80%4.98%-1.65%
R&D-18.91M28.27M43.77M53.35M72.61M87.54M108.79M140.14M202.07M207.27M273.22M324.17M323.15M317.94M
R&D as % of Total Revenue-3.12%3.63%4.68%5.01%4.88%4.44%4.05%4.35%5.46%5.21%7.57%11.19%12.68%14.65%
Interest Expense3.86M7.03M2.11M8.95M9.29M4.66M15.70M49.59M67.98M69.81M60.69M35.63M34.45M23.04M21.54M
Interest Expense % of Total Revenue0.74%1.16%0.27%0.96%0.87%0.31%0.80%1.85%2.11%1.88%1.52%0.99%1.19%0.90%0.99%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets505.16M629.52M837.02M1.22B2.37B2.70B3.58B4.56B5.50B6.36B6.57B8.16B8.12B7.98B7.99B
Total Liabilities193.39M186.54M232.53M424.27M371.71M415.01M970.12M1.69B2.17B2.36B2.03B1.63B1.51B1.55B1.69B
Total Equity311.77M442.98M604.48M792.05M2.00B2.24B2.50B2.70B3.13B3.80B4.30B6.29B6.38B6.37B6.28B
Cash105.41M117.45M105.91M177.53M200.76M153.86M344.42M441.65M443.91M612.07M637.16M587.35M835.96M671.45M667.19M
Total Debt108.01M106.06M130.70M290.67M198.24M198.74M669.53M1.19B1.51B1.32B1.12B701.22M320.13M446.00M-
Net Debt2.60M-11.40M24.79M113.14M-2.51M44.89M325.11M752.10M1.06B709.18M478.29M113.87M-170.79M-225.45M113.64M

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow85.55M110.96M98.39M115.09M33.18M49.32M79.03M193.91M459.52M1.09B1.62B843.22M912.09M633.80M602.33M
Investing Cash Flow-75.54M-61.04M-102.94M-158.92M-869.95M-83.03M-236.14M-419.01M-514.45M-502.52M-686.81M-1.83B-513.62M-677.47M-
Financing Cash Flow33.10M-36.68M-13.25M112.25M855.93M-43.64M391.05M277.35M94.32M-433.37M-894.69M930.05M-152.75M-126.78M-
Capital Expenditure82.99M69.03M107.56M161.10M221.31M388.75M462.36M529.95M504.67M501.32M601.78M987.74M877.90M963.02M749.07M
Free Cash Flow2.56M41.93M-9.17M-46.01M-188.13M-339.43M-383.32M-336.04M-45.15M592.73M1.01B-144.52M23.61M-329.22M-146.74M
Dividends Paid5.48M34.73M37.90M47.72M54.35M54.15M77.00M122.75M89.28M105.41M238.44M286.64M244.64M115.19M83.74M
FCF to OCF2.99%37.79%-9.32%-39.97%-566.93%-688.29%-485.01%-173.30%-9.83%54.18%62.78%-17.14%2.59%-51.94%-24.36%
Dividend Paid to FCF214.19%82.83%-413.45%-103.73%-28.89%-15.95%-20.09%-36.53%-197.72%17.78%23.49%-198.33%1036.39%-34.99%-57.07%

Earnings

Report DateAug 17, 2015Oct 23, 2015Feb 26, 2016Apr 25, 2016Aug 22, 2016Oct 19, 2016Feb 28, 2017Apr 17, 2017Jul 31, 2017Oct 25, 2017Feb 26, 2018Apr 20, 2018Jul 30, 2018Oct 25, 2018Apr 26, 2019Jul 30, 2019Oct 29, 2019Feb 24, 2020Apr 23, 2020Jul 30, 2020Oct 28, 2020Feb 25, 2021Apr 27, 2021Jul 30, 2021Oct 26, 2021Apr 27, 2022Jul 15, 2022Oct 24, 2022Apr 24, 2023Jul 28, 2023Oct 25, 2023Apr 24, 2024Aug 1, 2024Oct 22, 2024Apr 28, 2025Aug 1, 2025Oct 25, 2025Apr 30, 2026Jul 31, 2026
EPS Estimate---------0.200.18----------------------------
EPS Actual0.180.100.100.120.170.140.120.140.200.190.140.180.240.220.210.270.260.200.140.420.460.410.560.390.480.340.330.320.190.090.150.070.130.130.040.020.010.010.04
Surprise----------5.00%-22.22%----------------------------
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market----

Key Statistics & Ratios

Market Cap5.76B
Enterprise Value5.81B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.71
Price / Book0.90
EPS-0.06
Book Value10.43
Revenue (TTM)2.13B
Gross Profit (TTM)1.18B
EBITDA351.72M
Profit Margin-1.67%
Operating Margin0.30%
Return on Equity-0.76%
Return on Assets-0.50%
Shares Outstanding604.67M
Shares Float369.95M
Beta0.20
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.10May 28, 2025
20241×
0.15Jul 3, 2024
20231×
0.35May 29, 2023
20221×
0.47May 19, 2022
20211×
0.43Jun 1, 2021
20201×
0.19Jun 17, 2020
20191×
0.16Jul 2, 2019
20181×
0.14May 29, 2018
20171×
0.11May 31, 2017
20161×
0.09Jun 8, 2016

Stock Splits

  • Jun 8, 201630:10